Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock, no par value
-
Number of holders
-
28
-
Total shares
-
21.2M
-
Shares change
-
+245K
-
Total reported value, excl. options
-
$18.3M
-
Value change
-
+$227K
-
Number of buys
-
5
-
Number of sells
-
-15
-
Price
-
$0.86
Significant Holders of Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) as of Q3 2022
30 filings reported holding CYCN - Cyclerion Therapeutics, Inc. - Common Stock, no par value as of Q3 2022.
Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) has 28 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 21.2M shares
.
Largest 10 shareholders include Slate Path Capital LP (7.16M shares), FMR LLC (3.41M shares), MFN Partners Management, LP (3.39M shares), Artal Group S.A. (2.78M shares), VANGUARD GROUP INC (1.65M shares), GEODE CAPITAL MANAGEMENT, LLC (584K shares), BlackRock Inc. (361K shares), TRUSTCORE FINANCIAL SERVICES, LLC (293K shares), RENAISSANCE TECHNOLOGIES LLC (283K shares), and Diametric Capital, LP (244K shares).
This table shows the top 28 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.